Raymond James Financial
DNTH icon

Raymond James Financial’s Dianthus Therapeutics DNTH Stock Holding History

Raymond James Financial’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Buy
+15,088
New +$874K ﹤0.01% 3694
2025
Q4 		– Sell
-11,245
Closed -$442K – 5205
2025
Q3 		$442K Buy
11,245
+9,815
+686% +$251K ﹤0.01% 4185
2025
Q2 		$26.6K Buy
+1,430
New +$26.8K ﹤0.01% 5468

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James Financial's DNTH Position: Q1 2026 in Review

Raymond James Financial opened a new position in Dianthus Therapeutics (DNTH) in Q1 2026: 15,088 shares worth $1.27M. The stake represents ﹤0.01% of the portfolio and ranks #3694 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in DNTH as recently as Q3 2025.

Raymond James Financial first reported a position in DNTH in Q2 2025 and has held it in 3 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Raymond James Financial held 15,088 shares of Dianthus Therapeutics worth $1.27M as of Q1 2026.
  • Dianthus Therapeutics was a new Raymond James Financial position in Q1 2026.
  • Dianthus Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3694 holding.
  • Raymond James Financial first reported a position in Dianthus Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.